Promed Bioscience is a highly innovative biotech company based in the European Union, specializing in the development and supply of highly purified medical-grade collagen. The company operates in the research, skincare, and medical markets, providing advanced collagen-based biomaterials for a variety of applications. Promed Bioscience serves a diverse range of clients, including research institutions, skincare product manufacturers, and medical practitioners. The company's business model revolves around the extraction and purification of collagen from animal tissue sources, using proprietary methods to retain the fibrillar structure and enhance biocompatibility, biodegradability, and low antigenicity. Promed Bioscience generates revenue by selling its ultrapure atelocollagen and fibrillar collagen products, which are used in cell culture gels, tissue engineering scaffolds, high-end skincare products, nutraceuticals, and medical applications such as skin regeneration, wound care, and surgical implants. The company has also entered into a partnership with the US-based business accelerator, Kinisis Ventures, to further expand its market reach.

Keywords: biotech, collagen, biomaterials, research, skincare, medical, atelocollagen, tissue engineering, wound care, implants.